Last checked at 
Physiomics PLC - oncology consultant based in Oxford - Secures further deals with existing client Germany's Merck KGaA. Says the two deals are expected to be completed by the end of calendar 2021. "These projects involve simulations of clinical efficacy of drug products in Merck's DNA damage/repair portfolio," Physiomics says.
Current stock price: 6.35 pence, up 4.1% on Friday
Year-to-date change: down 14%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.